Cargando…
Examination of Setarud (IMOD™) in the management of patients with severe sepsis
BACKGROUND AND THE PURPOSE OF THE STUDY: Analysis of current immunomodulating strategies indicates that monovalent approaches are unlikely to restore immunostasis or achieve complete therapy of sepsis. Setarud (IMOD) as a mixture of urtica, carotenoids, urea, and selenium has been recently patented...
Autores principales: | Mahmoodpoor, A., Eslami, K., Mojtahedzadeh, M., Najafi, A., Ahmadi, A., Dehnadi-Moghadam, A., Mohammadirad, A., Baeeri, M., Abdollahi, M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Tehran University of Medical Sciences
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3232081/ https://www.ncbi.nlm.nih.gov/pubmed/22615589 |
Ejemplares similares
-
Efficacy of Setarud (IMOD™), a novel electromagnetically-treated multi-herbal compound, in mouse immunogenic type-1 diabetes
por: Mohseni-Salehi-Monfared, Seyed Sajad, et al.
Publicado: (2010) -
The effect of Setarud (IMOD(TM)) on angiogenesis in transplanted human ovarian tissue to nude mice
por: Hormozi, Maryam, et al.
Publicado: (2015) -
Effects of IMOD™ and Angipars™ on mouse D-galactose-induced model of aging
por: Ghanbari, Samane, et al.
Publicado: (2012) -
Positive effect of septimeb™ on mortality rate in severe sepsis: a novel non antibiotic strategy
por: Eslami, Kaveh, et al.
Publicado: (2012) -
The in vitro anti-viral potential of Setarud (IMOD™), a commercial herbal medicine with protective activity against acquired immune deficiency syndrome in clinical trials
por: Zabihollahi, Rezvan, et al.
Publicado: (2012)